|
Eine Ebene nach oben |
Gruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 3
Zeitschriftenartikel
Cristofanilli, Massimo; Rugo, Hope S.; Im, Seock-Ah; Slamon, Dennis J.; Harbeck, Nadia; Bondarenko, Igor; Masuda, Norikazu; Colleoni, Marco; DeMichele, Angela; Loi, Sherene; Iwata, Hiroji; O'Leary, Ben; Andre, Fabrice; Loibl, Sibylle; Bananis, Eustratios; Liu, Yuan; Huang, Xin; Kim, Sindy; Frean, Maria Jose Lechuga und Turner, Nicholas C.
(2022):
Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2(- )ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study.
In: Clinical Cancer Research, Bd. 28, Nr. 16: S. 3433-3442
O'Shaughnessy, Joyce; Schwartzberg, Lee; Piccart, Martine; Rugo, Hope S.; Yardley, Denise A.; Cortes, Javier; Untch, Michael; Harbeck, Nadia; Wright, Gail S.; Bondarenko, Igor; Glaspy, John; Nowecki, Zbigniew; Kayali, Fadi; Chan, Arlene; Levy, Christelle; Liu, Mei-Ching; Kim, Sung-Bae; Lemieux, Julie; Manikhas, Alexey; Tolaney, Sara; Lim, Elaine; Gombos, Andrea; Stradella, Agostina; Pegram, Mark; Fasching, Peter; Mangel, Laszlo; Semiglazov, Vladimir; Dieras, Veronique; Gianni, Luca; Danso, Michael A.; Vacirca, Jeff; Kroll, Stew; O'Connell, Joseph; Tang, Kevin; Wei, Thomas und Seidman, Andrew
(2021):
Results From CONTESSA: A Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2-, Hormone Receptor+ Metastatic Breast Cancer Who Have Previously Received a Taxane.
In: Clinical Advances in Hematology & Oncology, Bd. 19, Nr. 2: S. 12-13
Cristofanilli, Massimo; Turner, Nicholas C.; Bondarenko, Igor; Ro, Jungsil; Im, Seock-Ah; Masuda, Norikazu; Colleoni, Marco; DeMichele, Angela; Loi, Sherene; Verma, Sunil; Iwata, Hiroji; Harbeck, Nadia; Zhang, Ke; Theall, Kathy Puyana; Jiang, Yuqiu; Bartlett, Cynthia Huang; Koehler, Maria und Slamon, Dennis
(2016):
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.
In: Lancet Oncology, Bd. 17, Nr. 4: S. 425-439